Exposure–Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study
Conclusions
In Japanese patients, there were no associations or only shallow relationships between DAA exposures and peripheral edema or laboratory abnormalities. Consequently, therapeutic drug monitoring is not expected to be beneficial in managing patients on the 2-DAA regimen.
Trial registration
ClinicalTrials.gov identifier, NCT02023099.
Funding
AbbVie Inc.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Bilirubin | Calcium | Cirrhosis | Drugs & Pharmacology | Hepatitis | Hepatitis C | Laboratory Medicine | Norvir | Study